Monday, September 14, 2026

LA FC Signs Armin Gibr: What This Transfer Means for the Team’s Title Hopes

LA FC has signed Bayern Munich forward Armindo Sieb on a 3+1 contract, awaiting international transfer certificate and P-1 issuance.

From CDMA to AI Highways: What’s Next for South Korea’s Telecom Industry?

SK Telecom celebrates 30 years of CDMA technology, highlighting its impact on telecommunications and the rise of AI infrastructure.

Korean Entrepreneurs Invited to VIP Lunch with Trump at the $TRUMP Meme Coin Conference

Korean entrepreneurs Lee Seung-yoon and Song Chi-hyung to speak at Trump's event for meme coin holders, discussing AI and data infrastructure.

Tag: Medipost

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Unlocking the Future: Why 340,000 Families Trust Celltrion’s Cord Blood Banking in 2026

Medipost announces that its brand, Celltrion, has surpassed 340,000 cord blood storage units in South Korea.

MediPost Signs CDMO Agreement With Qstem for Dermal Papilla Cell Culture Medium

MediPost will establish a commercial-scale production system for Qstem’s hiPSC-based dermal papilla cell culture medium, expanding its CDMO business beyond cell therapies.

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial

Medipost's CARTISTEM therapy shows significant efficacy in Phase 3 trials for knee osteoarthritis in Japan, enhancing global competitiveness.

Medipost’s CARTISTEM® Completes Phase 3 Trials in Japan: What This Means for Knee Osteoarthritis Treatment

Medipost completes Phase 3 trial for CARTISTEM in Japan, targeting knee osteoarthritis treatment and planning U.S. trial enrollment soon.

Medipost’s Cartistem: Achieving 3000 Knee Cartilage Restoration Surgeries – A Game Changer for Osteoarthritis Treatment

Medipost's Cartistem therapy reaches 3,000 procedures for cartilage restoration, proving its safety and efficacy for knee osteoarthritis.

U.S. Surgeons Get Hands-On With Korea’s Game-Changing Stem Cell Therapy

Medipost's Cartistem® training program for U.S. orthopedic specialists enhances global collaboration and prepares for Phase 3 trials.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.